content_top
34 companies, 1 interpreter! Insight, foresight
and recommendation 

Mesoblast Limited (MESO)

0
0.00
(0.00%)
 Sep 11, 4:00PM EDT
content_middle

Mesoblast Limited (MESO) develops cell-based medicines.

MESO has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.

MESO’s products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes.

MESO has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Company Website
Previous Close: 
0.00
Open: 
5.88
Bid: 
5.71
Ask: 
5.84
1yr Target Price: 
13.29
Day's Range: 
5.72 - 5.95
52wk Range: 
0.26 - 1.35
Volume: 
34624
Average Daily Volume: 
25933
Market Capitalization: 
0.00M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
0.00M
content_right

Pages